Clinical trials
Ovarian cancer clinical trials
Cancer that starts in the ovaries, often found at a later stage. We’re tracking 609 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07181720RecruitingPhase 1
CD70-targeted CAR-T therapy for advanced solid tumors
This trial tests a new treatment called CAR-T that targets a protein called CD70 on cancer cells. It is for people with advanced solid tumors that have not responded to or cannot tolerate standard treatments.
Hefei, AnhuiAges 18 years+ - NCT06566716Recruiting
Blood test to check for cancer risk before ovarian mass surgery
This study tests a new blood test to help doctors determine if an ovarian mass is cancerous before surgery. If you are a woman over 18 with an ovarian cyst or mass that needs surgery, this test could help guide your care.
Chandler, ArizonaAges 18 years+ - NCT05974150Recruiting
Remote symptom monitoring for several blood and cancer types
This study checks how well remote (at-home) symptom check-ins work for people with certain cancers. It may help patients and clinicians spot problems earlier and improve day-to-day care during treatment and beyond.
New Haven, ConnecticutAges 18 years+ - NCT06682988RecruitingPhase 2
New treatment for advanced ovarian cancer
This trial tests a drug called mirvetuximab soravtansine for people with platinum-resistant ovarian, peritoneal, or fallopian tube cancer that has high levels of a protein called folate receptor-alpha (FRα). It is given through a vein (IV) and aims to stop cancer from growing.
Sarasota, FloridaAges 18 years+ - NCT05704621RecruitingPhase 2
Surgery after PARP inhibitor failure in returning ovarian cancer
This trial tests whether doing additional (“secondary”) tumor-removal surgery can help people with ovarian, fallopian tube, or primary peritoneal cancer that has returned after PARP inhibitor maintenance. It focuses on people whose cancer can likely be fully removed and who are considered good candidates for surgery and follow-up treatment.
SeoulAges 18 years+ - NCT06533709Recruiting
Can PET-CT predict ovarian cancer surgery success?
This trial uses PET-CT scans to create a model that predicts how completely advanced ovarian cancer can be removed during surgery. It may help doctors plan the best treatment for you.
Guangzhou, GuangdongAges 18–80 - NCT07572409Recruiting
Lymph Node Surgery for Advanced Ovarian Cancer
This study tests whether removing enlarged lymph nodes near the heart and lungs during surgery for advanced ovarian cancer can help you live longer and feel better. You must have already had surgery to remove most of your tumor and have specific lymph node changes on imaging.
Changchun, JilinAges 18–70 - NCT04361370Enrolling by invitationPhase 2
Olaparib plus pembrolizumab and bevacizumab after ovarian cancer
This trial tests whether adding olaparib, pembrolizumab, and bevacizumab as ongoing (“maintenance”) treatment can help control platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer that has responded to prior chemotherapy. It focuses on people whose tumors do NOT have BRCA1/2 gene mutations.
SeoulAges 20 years+ - NCT03393962Enrolling by invitationPhase 1/Phase 2
Antigen-targeted immune cell treatment for high-risk ovarian cancer
This early-phase trial tests a lab-made immune cell treatment designed to recognize ovarian cancer and attack it. It may help people with high-risk ovarian cancer who still need effective options.
Shenzhen, GuangdongAges 10–80 - NCT06617923RecruitingPhase 2
Senaparib and Temozolomide for ARID1A-Mutated Ovarian Cancer
This trial tests a combination of two drugs, senaparib and temozolomide, for women with a specific type of ovarian cancer that has come back or is resistant to platinum-based chemotherapy. It is for patients whose tumor has a change in the ARID1A gene.
Baltimore, MarylandAges 18 years+ - NCT07489287RecruitingPhase 1
GB-5267 for platinum-resistant ovarian, peritoneal, or fallopian tube cancer
This trial tests a new cell therapy (GB-5267) for people with platinum-resistant ovarian, peritoneal, or fallopian tube cancer. It requires multiple tumor biopsies and aims to see if the treatment can help when standard chemo stops working.
Buffalo, New YorkAges 18 years+ - NCT06819215RecruitingPhase 1/Phase 2
VB15010 for advanced solid tumors with HRR gene mutation
This trial tests an oral medication (VB15010) in people with advanced solid tumors that have a specific DNA repair gene mutation (called HRR mutation). The goal is to see if the drug can stop or slow down cancer growth.
Jinan, ShandongAges 18–75 - NCT06365853RecruitingPhase 2
Study of eye safety during treatment with MIRV for recurrent ovarian cancer
This trial tests a targeted drug called mirvetuximab soravtansine (MIRV) for recurrent ovarian cancer that has high levels of a protein called FRα. The study focuses on monitoring and preventing eye-related side effects, which are common with this treatment.
Los Angeles, CaliforniaAges 18 years+ - NCT07495384Recruiting
CapsuleX and cisplatin for platinum-resistant ovarian cancer
This study tests a new treatment combination (CapsuleX plus cisplatin) for people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if this combination can help when the cancer has progressed within 6 months of last platinum treatment.
Changchun, JilinAges 18 years+ - NCT05231122RecruitingPhase 2
Pembrolizumab and bevacizumab for recurrent ovarian cancer
This trial studies whether adding pembrolizumab to bevacizumab (and sometimes an anti-CD40 drug) can help control recurrent ovarian, fallopian tube, or primary peritoneal cancer. It also looks at whether the treatment can shrink tumors and keep them from growing for longer.
Buffalo, New YorkAges 18 years+ - NCT06760507Recruiting
Family history screening for BRCA cancers in rural clinics
This trial tests a program to help women in rural public health clinics learn about their family history of BRCA-related cancers. It aims to increase genetic screening and counseling for those at higher risk.
Atlanta, GeorgiaAges 25 years+ - NCT07407062Recruiting
Study of folate receptor alpha in ovarian cancer tissue
This study looks at a marker called folate receptor alpha in tissue samples from people with ovarian, fallopian tube, or primary peritoneal cancer that has returned. The goal is to see how common this marker is, which may help guide future treatment options.
Rome, RomaAges 18 years+ - NCT05737303RecruitingPhase 3
First-line chemotherapy comparison for advanced ovarian cancer
This Phase 3 trial compares two chemotherapy drug approaches (nab-paclitaxel vs another taxane drug) as the first treatment for advanced ovarian, fallopian tube, or peritoneal cancer. It aims to find which option works better and is tolerated better in people with stage III–IV disease.
Guangzhou, GuangdongAges 18–75 - NCT05053230Recruiting
At-home integrative program for people living with cancer
This study tests an at-home integrative medicine program (supportive, whole-person care) to see if it helps symptoms like fatigue for people affected by cancer. You may be assigned to the program or a comparison group, and you’ll complete questionnaires and study check-ins from home.
Basking Ridge, New JerseyAges 18 years+ - NCT05242861Recruiting
Reviewing outcomes after brachytherapy for women’s cancers
This study looks back at medical records to understand results after brachytherapy (a form of cancer radiation delivered from inside or close to the tumor) in women with gynecologic cancer. It may help doctors improve future treatment decisions, but you would not have to receive an experimental treatment.
Hangzhou, ZhejiangAges 18–80 - NCT05410717RecruitingPhase 1
CAR-NK cell therapy for certain solid tumors
This early-phase trial tests a lab-made immune cell treatment for advanced solid tumors that show specific targets (including Claudin 6, GPC3, Mesothelin, or AXL). It may help the immune system better recognize and kill tumor cells, but eligibility depends on test results and your overall health.
Guangzhou, GuangdongAges 18–75 - NCT07182149RecruitingPhase 1
Testing a new drug for advanced solid tumors
This trial tests a new drug called NRM-823 for people with several types of advanced cancer that have stopped responding to standard treatments. The goal is to see if the drug is safe and how well it works.
Denver, ColoradoAges 18 years+ - NCT06249308Recruiting
Liquid biopsy test for early ovarian cancer detection
This study is testing a blood test to see if it can catch ovarian cancer early. You may be eligible if you have been recently diagnosed with ovarian cancer and haven't started treatment yet.
Guangzhou, GuangdongAges 40–75 - NCT06588322Recruiting
Detecting gene changes in blood of ovarian cancer patients on PARP inhibitor
This study looks for specific gene mutations in the blood of ovarian cancer patients who have a BRCA mutation and are starting first-line maintenance therapy with a PARP inhibitor called Olaparib. It aims to better understand how these mutations may affect treatment response.
AngersAges 18 years+
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for ovarian cancer?
- Yes. Clin2 currently lists 609 recruiting ovarian cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a ovarian cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a ovarian cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.